Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Zacks Investment Research Inc.
|
$12.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Novo Nordisk A/S End Deal With Pacira Pharmaceuticals Inc-Reuters
Reuters reported that Pacira Pharmaceuticals Inc said that Novo Nordisk A/S has terminated an agreement to develop a drug using Pacira's technology. Novo had rights to develop a drug using Pacira's drug delivery technology that encapsulates drugs without changing their molecular structure and then releases them over a desired time period. Pacira said in a regulatory filing that the termination of the deal will be effective 60 days from the day of the notice.
Latest Developments for Pacira Pharmaceuticals Inc
- Pacira Pharmaceuticals Inc Announces Data From Analysis Of Postsurgical Pain Management
- Pacira Pharmaceuticals Inc Announces New Data Supporting Use Of Exparel Via Infiltration Into Transversus Abdominis Plane
- Pacira Pharmaceuticals Inc Reiterates FY 2012 Revenue Guidance-Conference Call
- Pacira Pharmaceuticals Inc Issues FY 2012 Revenue Guidance-Conference Call
Latest Key Developments in Pharmaceuticals
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 million
- H Lundbeck A/S Lowers FY 2013 EBIT Guidance Following European Commission's Fine of EUR 93 million-DJ
- Suheung Capsule Co Ltd to Merge with Subsidiary
- FDA Probes Deaths Of Two Patients On Eli Lilly And Co's Schizophrenia Drug-Reuters
- Share this
- Link this
- Digg this
Follow Reuters